Latest Clinical Trial Update: SQZ™ APC Investigational Therapy Induced Radiographic, Symptomatic and Immune Response as Monotherapy in Post-Checkpoint HPV+ Solid Tumor Patient

About Our Approach

We use a patient’s own cells to manufacture a personalized therapy. After blood collection, we isolate target cell types, use our SQZ™ technology to engineer their functions and administer them back to the patient. This manufacturing process typically takes less than 24hrs and a patient can receive their first dose about a week after blood collection. Once administered, SQZ™ engineered cells are designed to home to specialized immune structures, such as the lymph nodes and spleen, and direct the patient’s immune system to target disease.

We have clinical programs in oncology and preclinical programs for autoimmune diseases (e.g. celiac disease, type 1 diabetes) and infectious diseases (e.g. chronic hepatitis B).

The Patient Experience


No preconditioning required

No lengthy hospital stays

~1 week manufacturing turnaround time

Administration is a simple syringe push
CONTACT US

Patients and their physicians can expect rapid answers to questions about our clinical trials. Your time is important, and we will endeavor to respond with urgency.

patientadvocacy@sqzbiotech.com

Active Enrollment · Oncology

SQZ Biotech is actively enrolling in the following trials for patients with HPV+ cancers. Currently, the majority of our clinical trial sites are based in the United States, but we have started to expand to other countries. For patients who do not live near one of our trial sites, we will assist with domestic and international travel and accommodations to the nearest clinical trial hospital and cover all reasonable and related expenses.

Enrolling HPV+ Cancers

  • Anal
  • Cervical
  • Head and Neck
  • Penile
  • Rectal
  • Vaginal
  • Vulvar

Eligibility

  • Male or Female 18 years of age or older
  • Histologically confirmed incurable or metastatic sold tumors that are HPV16+
  • HLA-A*02 genotype positive
  • Cancer progression after at least one available standard therapy for incurable disease, or patient is intolerant to or refuses standard therapy(ies) or has a tumor for which no standard therapy(ies) exist
SQZ-PBMC-HPV · PHASE 1/2 CLINICAL TRIAL
APC therapeutic candidate derived from patient’s own white blood cells
  • Designed to present specific tumor antigens to the body’s endogenous CD8 T cells
  • Administered as monotherapy or in combination with checkpoint inhibitors atezolizumab or ipilimumab
  • Encouraging initial monotherapy clinical trial data was presented at the 2021 American Society of Clinical Oncology (ASCO) annual meeting. Additional clinical data was presented at ESMO IO 2021 demonstrating a clinical and immune response in a heavily treated patient. See our ESMO-IO press release and oral presentation

Learn about the science behind SQZ-PBMC-HPV
Trial and enrollment details

SQZ-AAC-HPV · PHASE 1/2 CLINICAL TRIAL
AAC therapeutic candidate derived from patient’s own red blood cells
  • Designed to transport tumor-specific antigen and activating adjuvant to a patient’s own antigen presenting cells in vivo
  • Administered as a monotherapy or in combination with checkpoint inhibitors ipilimumab or nivolumab
  • In preclinical studies, SQZ™ AACs have demonstrated robust immune responses, CD8 T cell infiltration, and correlated tumor reduction

Learn about the science behind SQZ-AAC-HPV
Trial and enrollment details

SQZ-PBMC-HPV ENROLLING SITES

  • HonorHealth, Scottsdale, AZ
  • Cedars-Sinai Medical Center, Los Angeles, CA
  • University of Colorado, Aurora, CO
  • University of Kansas Cancer Center, Kansas City, KS
  • Massachusetts General Hospital, Boston, MA
  • University of Nebraska Medical Center, Omaha, NE
  • Providence Cancer Institute, Portland, OR
  • Vanderbilt University Medical Center, Nashville, TN
  • Princess Margaret Cancer Centre, Toronto, Ontario, Canada

SQZ-AAC-HPV ENROLLING SITES

  • UC San Diego Moores Cancer Center, La Jolla, CA
  • City of Hope, Duarte, CA
  • More sites expected to open soon!

Patient Advocacy

We are committed to advancing the clinical development of cell therapies that are safe, effective and accessible to patients worldwide. We are actively engaged with leading advocacy organizations working to support patients and their families living with cancer. For additional information on HPV+ cancers, the following organizations can provide educational and other resources.

We are not responsible for content provided by these organizations.